Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.

MLA

McMurray, John J. V., et al. “Resource Utilization and Costs in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Programme.” European Heart Journal, vol. 27, no. 12, June 2006, pp. 1447–58. EBSCOhost, https://doi.org/10.1093/eurheartj/ehl016.

APA

McMurray, J. J. V., Andersson, F. L., Stewart, S., Svensson, K., Solal, A. C., Dietz, R., Vanhaecke, J., van Veldhuisen, D. J., Ostergren, J., Granger, C. B., Yusuf, S., Pfeffer, M. A., & Swedberg, K. (2006). Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 27(12), 1447–1458. https://doi.org/10.1093/eurheartj/ehl016

Chicago

McMurray, John J V, Fredrik L Andersson, Simon Stewart, Klas Svensson, Alain Cohen Solal, Rainer Dietz, Johan Vanhaecke, et al. 2006. “Resource Utilization and Costs in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Programme.” European Heart Journal 27 (12): 1447–58. doi:10.1093/eurheartj/ehl016.